Brii Biosciences has reported that the National Institutes of Health (NIH)’s ACTIV-2 clinical trial in the US completed enrolment for the Phase III part assessing its combination treatment, BRII-196 plus BRII-198, for Covid-19.

Obtained from convalesced Covid-19 patients, BRII-196 and BRII-198 are non-competing monoclonal antibodies that neutralise SARS-CoV-2.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Funded by the NIH unit National Institute of Allergy and Infectious Diseases (NIAID), the randomised, blinded, controlled adaptive platform ACTIV-2 master protocol is led by the NIAID-sponsored AIDS Clinical Trials Group.

The trial is analysing the safety and efficacy of various experimental drugs for symptomatic Covid-19 treatment in non-hospitalised adults.

In January this year, the NIH initiated the Phase II/III ACTIV-2 trial of Brii Biosciences’ combination therapy.

The Phase III part of the trial will assess the combination treatment in 846 outpatients enrolled at centres in the US, Brazil, South Africa, Mexico and Argentina.

Subjects with symptomatic Covid-19 who are at increased risk of clinical progression are part of the trial.

The combined primary goal of the trial is to evaluate hospitalisations and death in the treatment arm as against placebo following 28 days of therapy.

The progression to the Phase III part comes after the combination met pre-defined, study-defined safety and efficacy goals in the Phase II segment.

After the conclusion of the trial, ACTIV-2 dataset analysis will comprise subjects enrolled between January and July this year, a period when a quick emergence of new SARS-CoV-2 variants was observed worldwide.

Bri Biosciences added that clinical efficacy results of the combination therapy by variant type will be assessed as part of the analysis.

So far, the BRII-196 plus BRII-198 combination was observed to be generally safe and well-tolerated in Phase I and Phase II trials.

Furthermore, the combination demonstrated activity against key SARS-CoV-2 variants of concern, including Alpha, Beta, Gamma, Epsilon and Delta variants during in vitro pseudovirus testing.

A Phase II trial of the combination treatment is underway in China.

In March last year, Brii Biosciences signed a memorandum of understanding with Columbia University to provide funding for research on solutions to treat, prevent and diagnose coronaviruses, including Covid-19.